The Effect of Antibiotic Eye Drops on the Nasal Microbiome in Healthy Subjects
NCT ID: NCT05287425
Last Updated: 2025-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
20 participants
INTERVENTIONAL
2019-08-12
2023-08-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There is evidence that topical non-antibiotic eye drops might have an effect on the nasopharyngeal mucosal flora. This seems logical due to the anatomical connection through the nasolacrimal duct and the fact that up to 80% of topically administered drug diffuse into the systemic circulation through the highly vascularized nasopharyngeal mucosa. However, in the literature no data on the effect of antibiotic eye drops on the nasal or pharyngeal microbiome are currently available.
Recently, new, non-culture based techniques for assessment of the bacterial microbiome have been developed, so-called "next-generation sequencing" (NGS). NGS utilizes universal primers targeting the 16S rRNA gene, which is ubiquitous across most bacteria. With this technique, it is possible to gain information about a wide range of the bacterial microbiome and not only on pre-selected species.
In the present study, NGS will be used to investigate the effect of antibiotic eye drops on the nasal and pharyngeal microbiome. For this purpose, healthy subjects will be randomized to either receive eye drops containing gentamicin, ciprofloxacin or topical lubricants as control. As secondary outcome, prevalence of bacterial resistance genes, as well as signs and symptoms of ocular surface damage will be assessed.
The study will be carried out in 2 parts. Since both formulations of topical antibiotics contain benzalkonium chloride which also has a potential effect on the nasal and pharyngeal mucosal flora, it is unknown how much benzalkonium chloride would contribute to changes in the nasal microbiome after administration of topical antibiotics. To overcome this problem, first a pilot study in 20 subjects will be performed in which subjects will be randomized to receive either eye drops containing gentamicin, ciprofloxacin, preservative-containing topical lubricants or preservative-free topical lubricants. Based on the results of this pilot study, the control for the main part of the study will be chosen, depending on the effect on the bacterial microbiome. The results of the pilot study could also provide useful data to adjust the sample size for the main study part. In the main study, 60 subjects will be randomized to receive gentamicin, ciprofloxacin or lubricant eye drops. The same examinations as described above will be performed after 1 week treatment as well as 1 week and 3 months after treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Change in Ocular Flora Resistance From Repeated Topical Antibiotic Use
NCT01181713
The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study
NCT05655689
Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
NCT02432807
Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics
NCT00831961
Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization
NCT05322148
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gentamicin eye drops
4 drops daily in both eyes for 7 ± 1 days
Gentamicin Ophthalmic
4 drops daily in both eyes for 7 ± 1 days
Ciprofloxacin eye drops
4 drops daily in both eyes for 7 ± 1 days
Ciprofloxacin Ophthalmic
4 drops daily in both eyes for 7 ± 1 days
Povidone eye drops unpreserved
4 drops daily in both eyes for 7 ± 1 days
Povidone Ophthalmic
4 drops daily in both eyes for 7 ± 1 days
Povidone eye drops preserved
4 drops daily in both eyes for 7 ± 1 days
Povidone and Benzalkonium Chloride Ophthalmic
4 drops daily in both eyes for 7 ± 1 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gentamicin Ophthalmic
4 drops daily in both eyes for 7 ± 1 days
Ciprofloxacin Ophthalmic
4 drops daily in both eyes for 7 ± 1 days
Povidone Ophthalmic
4 drops daily in both eyes for 7 ± 1 days
Povidone and Benzalkonium Chloride Ophthalmic
4 drops daily in both eyes for 7 ± 1 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal ophthalmic findings
* Tear Break Up Time \>10 seconds
* Schirmer I Test \> 10mm/5min
* Ametropia ≤ 6 diopters
* No use of topical eye or nasal drops in the last 3 months
Exclusion Criteria
* Participation in a clinical trial in the 3 weeks preceding the study
* Treatment in the previous 3 weeks with any drug (except intake of hormonal contraceptives)
* Treatment with topical or systemic antibiotics within 8 weeks before inclusion
* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
* History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs
* Known hypersensitivity to any of the components of the IMP under investigation or other study medication
* Pregnant or breast-feeding women
* Women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception (i.e. oral contraceptives, intra-uterine device, contraceptive implant or condoms)
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Doreen Schmidl
Assoc. Prof. PD, MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Clinical Pharmacology, Medical University of Vienna
Vienna, Vienna, Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OPHT-240518
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.